17 completed, 2 terminated, 1 active not recruiting, 1 withdrawn. 21 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 21 | Completed 17, Terminated 2, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow sonidegib: new trials by email Literature Review of sonidegib trials Research Report on sonidegib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors Pembrolizumab, Sonidegib - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8 | Phase 1 | Active not recruiting | Mayo Clinic | 36 | 2020-02-13 | 2026-03-18 |
| SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors Gemcitabine, ribociclib, sonidegib - Anaplastic Astrocytoma, Anaplastic Ependymoma | Phase 1 | Completed | St. Jude Children's Research Hospital | 68 | 2018-03-05 | 2024-05-31 |
| Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer LDE225 - Recurrent Ovarian Cancer | Phase 1 | Completed | University of Alabama at Birmingham | 15 | 2014-09-01 | 2026-02-09 |
| LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel Docetaxel, Prednisone, LDE225 - Prostate Cancer | Phase 1 | Withdrawn | Martin Gutierrez | 2014-07-01 | 2019-06-19 | |
| LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis LDE225 - Hepatocellular Carcinoma, Cirrhosis | Phase 1 | Completed | Jason K. Sicklick, M.D. | 9 | 2014-07-01 | 2019-03-05 |
| Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients LDE225, Docetaxel - Advanced Breast Cancer | Phase 1 | Completed | Spanish Breast Cancer Research Group | 12 | 2014-05-01 | 2023-04-03 |
| Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies Azacitidine, Decitabine, Laboratory Biomarker Analysis - Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome | Phase 1 | Completed | Mayo Clinic | 63 | 2014-05-01 | 2019-10-30 |
| Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT LDE225 - Graft Versus Host Disease | Phase 1 | Terminated | Massachusetts General Hospital | 17 | 2014-04-01 | 2018-03-19 |
| A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer LDE225 - Prostate Cancer | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 14 | 2014-04-01 | 2019-03-07 |
| LDE225 and Paclitaxel in Solid Tumors LDE225, Paclitaxel - Solid Tumor, Ovarian Cancer | Phase 1 | Completed | Swiss Cancer Institute | 30 | 2013-09-01 | 2019-12-06 |
| A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF LDE225, INC424 - Primary Myelofibrosis, Thrombocytosis | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 50 | 2013-05-08 | 2020-04-15 |
| Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients LDE225, Wafarin, Bupropion - Advanced Solid Tumor | Phase 1 | Completed | Novartis Pharmaceuticals | 114 | 2013-04-01 | 2020-12-19 |
| Effect of Hepatic Impairment on LDE225.. LDE225 - Normal Hepatic Function, Impaired Hepatic Function | Phase 1 | Completed | Novartis Pharmaceuticals | 33 | 2013-03-01 | 2020-12-19 |
| Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors LDE225, BKM120 - Dose Escalation, Safety | Phase 1 | Completed | Novartis Pharmaceuticals | 120 | 2012-07-01 | 2020-12-19 |
| Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) LDE225, Etoposide and Cisplatin - Lung Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 19 | 2012-04-01 | 2017-08-17 |
| Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy Nilotinib + LDE225 - Philadelphia Chromosome Positive Chronic Myelogenous Leukemia | Phase 1 | Completed | Novartis Pharmaceuticals | 11 | 2012-01-01 | 2020-12-09 |
| Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma LDE225-600mg, Gemcitabine, nab-paclitaxel - Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 23 | 2011-12-27 | 2020-01-22 |
| LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan - Pancreatic Cancer | Phase 1 | Completed | Massachusetts General Hospital | 39 | 2011-12-01 | 2020-08-04 |
| A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB LDE225 - Medulloblastoma, Rhabdomyosarcoma | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 76 | 2011-02-01 | 2017-03-20 |
| An East Asian Study of LDE225 LDE225 - Advanced Solid Tumor Cancers, Medulloblastoma | Phase 1 | Completed | Novartis Pharmaceuticals | 45 | 2010-10-01 | 2020-12-19 |
Showing 20 of 21. Sign in to see all of them.
Medulloblastoma (4) · Astrocytoma (2) · Carcinoma, Basal Cell (2) · Glioblastoma (2) · Glioma (2) · Lung Neoplasms (2) · Neoplasm Metastasis (2) · Ovarian Neoplasms (2) · Polycythemia Vera (2) · Primary Myelofibrosis (2) · Prostatic Neoplasms (2) · Recurrence (2) · Thrombocythemia, Essential (2) · Blood Coagulation Disorders (1) · Blood Platelet Disorders (1)
Novartis Pharmaceuticals (8) · Massachusetts General Hospital (2) · Mayo Clinic (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Jason K. Sicklick, M.D. (1) · Martin Gutierrez (1) · Memorial Sloan Kettering Cancer Center (1) · Spanish Breast Cancer Research Group (1) · St. Jude Children's Research Hospital (1) · Swiss Cancer Institute (1) · University of Alabama at Birmingham (1)
United States (16) · Spain (5) · Canada (4) · Germany (4) · Italy (4) · United Kingdom (4) · Australia (3) · Belgium (3) · France (3) · Switzerland (2) · Bulgaria (1) · Denmark (1) · Hong Kong (1) · Ireland (1) · Israel (1)
Ana De Jesus-Acosta, MD (1) · Anastasios Stathis, MD (1) · Aref Al-Kali (1) · Charles A Leath, III, MD, MSPH (1) · Charles Rudin, MD (1) · Cristiana Sessa, Prof Dr med (1) · Emmanuel Antonarakis, M.D. (1) · Giles W. Robinson, MD (1) · Jason K. Sicklick, MD (1) · Jeffery W Clark, MD (1) · Mojun Zhu, M.D. (1) · Yi-Bin Chen, MD (1)
PMID 27467121, PMID 29296838, PMID 29948356, PMID 30042390, PMID 32634234, PMID 32736411
2008 (1), P30CA015083 (1)